Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5294327 | 0.72 | HPGD (0.34) | ALDH1A1 | |
| SCHEMBL442176 | 0.68 | ALDH1A1 (0.33) | ALDH1A1 | |
| 2-Aminopurine SCHEMBL5634 | 0.67 | ALDH1A1 (1.00) | ALDH1A1RXFP1 | |
| SCHEMBL31561546 | 0.67 | ALDH1A1 (0.53) | ALDH1A1RXFP1 | |
| SCHEMBL237122 | 0.67 | ALDH1A1 (0.53) | ALDH1A1RXFP1 | |
| SCHEMBL5758003 | 0.66 | — | — | |
| SCHEMBL190527 | 0.66 | KDM4E (0.46) | ALDH1A1 | |
| 2-Aminopurine SCHEMBL3144589 | 0.65 | ALDH1A1 (0.96) | ALDH1A1RXFP1 | |
| 2-Aminopurine SCHEMBL357699 | 0.65 | ALDH1A1 (0.96) | ALDH1A1RXFP1 | |
| SCHEMBL170860 | 0.65 | ALDH1A1 (0.52) | ALDH1A1RXFP1MAPKAPK2CLK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | claimed |
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | CHEMGENES CORPORATION | 2011-01-13 | — | — | US | claimed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-1301519-B2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-06 | — | — | US | disclosed |
| EP-3351548-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-3020712-B1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2018-07-04 | — | — | EP | disclosed |
| EP-0874858-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| WO-1997024361-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0502447-A1 | Tetrahydrofuran intermediates | Bristol-Myers Squibb Company (US) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | ITPA, NT5C2, NT5C3B | ALDH1A1 4166/4885RXFP1 4205/4885MAPKAPK2 4103/4885 |
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | ALDH1A1 808/4885RXFP1 4743/4885MAPKAPK2 3137/4885 |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | ALDH1A1 4577/4885RXFP1 4837/4885MAPKAPK2 1971/4885 |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | NSUN2, RNMT, POLRMT | ALDH1A1 1062/4885RXFP1 2944/4885MAPKAPK2 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.